Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€26.60
Change (%) Stock is Up 0.76 (2.94%)
Volume71,247
Data as of 10/19/17 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
10-Oct-2017ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
LYON, France--(BUSINESS WIRE)--Oct. 10, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has resubmitted to the European Medicine Agency (EMA) its Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of patients with relapsed or... 
 Printer Friendly Version
06-Oct-2017ERYTECH Files Registration Statement for Proposed Initial Public Offering in the United States
LYON, France--(BUSINESS WIRE)--Oct. 6, 2017-- ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP) (“ERYTECH”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its American ... 
 Printer Friendly Version
06-Oct-2017Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –September 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Oct. 6, 2017-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting righ... 
 Printer Friendly Version
28-Sep-2017ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL
Dose of 100 U/kg, which is the same dose used in other studies with eryaspase in adult acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and metastatic pancreatic cancer patients, was recommended for further evaluation of eryaspase in pivotal study in first line adult ALL LYON, France--(BUSINESS WIRE)--Sep. 28, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopha... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
11/13/17
Third Quarter 2017 Financial Results and Business Update: Press Release: Monday, November 13, 2017 (after market)
11/14/17 3:00 p.m. CET
Third Quarter 2017 Financial Results and Business Update: Conference Call
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources